Role of COX-2 inhibitors in cancer therapy.
Blanke
Charles
C
Oregon Health Science University, 3181 Southwest Sam Jackson Park Rd., Portland, OR 97201, USA. blankec@ohsu.edu
D016588:Anticarcinogenic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016718:Arachidonic Acid / Q000378:metabolism / Q000494:pharmacology; D003131:Combined Modality Therapy; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007527:Isoenzymes / Q000494:pharmacology*; D008565:Membrane Proteins; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000494:pharmacology*; D011878:Radiotherapy
D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D016718:Arachidonic Acid; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; C496511:PTGS1 protein, human; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases